Quest Diagnostics vs DexCom
Quest Diagnostics (DGX), health care, and DexCom (DXCM), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
DexCom is worth $30.6B on the stock market and Quest Diagnostics $28.2B: DexCom is valued at 8% more. Quest Diagnostics trades at 26.1 times earnings and DexCom at 32.2; operating margins in their latest fiscal years were 14.1% and 19.6%. Over the past year Quest Diagnostics's share price has moved +41.5% and DexCom's +35.6%.
Key facts
- Quest Diagnostics market value
- $28.2B
- DexCom market value
- $30.6B
- Quest Diagnostics P/E
- 26.1
- DexCom P/E
- 32.2
- Quest Diagnostics revenue
- $11BFY to 2025-12-31
- DexCom revenue
- $4.7BFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Quest Diagnostics | DexCom |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $28.2Blower | $30.6Bhigher |
| Revenue | $11Bhigher | $4.7Blower |
| Earnings | $992Mhigher | $836.3Mlower |
| Employees | 60,000higher | 11,000lower |
| Total assets | $16.2Bhigher | $6.3Blower |
| Valuation | ||
| P/E | 26.1lower | 32.2higher |
| P/S | 2.6lower | 6.6higher |
| P/B | 3.7lower | 12.1higher |
| Dividend yield | 1.29%higher | 0.00%lower |
| Profitability | ||
| Operating margin | 14.1%lower | 19.6%higher |
| Balance sheet | ||
| Net assets | $7.2Bhigher | $2.7Blower |
| Total liabilities | $8.9Bhigher | $3.6Blower |
| Total debt | $5.7B | — |
| Cash on hand | $420Mlower | $917.7Mhigher |
| Price change | ||
| Today | -2.23%lower | +0.53%higher |
| 1 year | +41.5%higher | +35.6%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Quest Diagnostics only (3)
DexCom only (2)
Percentages are each holding's share of that investor's reported portfolio. Who owns DGX · Who owns DXCM
More on Quest Diagnostics
Further comparisons
Quest Diagnostics against its closest peers
DexCom against its closest peers
Learn
Questions and answers
Which is bigger, Quest Diagnostics or DexCom?
By market value, DexCom is the larger: $30.6B against $28.2B for Quest Diagnostics. By revenue in its latest fiscal year, Quest Diagnostics is the larger: $11B against $4.7B for DexCom.
Which has the higher P/E ratio?
DexCom: 32.2, against 26.1 for Quest Diagnostics. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
DexCom: 19.6%, against 14.1% for Quest Diagnostics. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Quest Diagnostics: 1.29%, against 0.00% for DexCom. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Quest Diagnostics and DexCom?
None of the tracked superinvestors holds both in their latest 13F filing. 3 hold Quest Diagnostics and 2 hold DexCom.
Cite this page
Funkfolio, “Quest Diagnostics vs DexCom”, data as of 18 November 2026. https://funkfolio.com/compare/dgx-vs-dxcm
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.